Royce & Associates LP bought a new position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,700 shares of the biopharmaceutical company’s stock, valued at approximately $299,000.
A number of other institutional investors have also recently made changes to their positions in ITCI. BlackRock Fund Advisors increased its position in shares of Intra-Cellular Therapies by 2.6% in the first quarter. BlackRock Fund Advisors now owns 970,940 shares of the biopharmaceutical company’s stock worth $26,992,000 after buying an additional 24,482 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Intra-Cellular Therapies by 2.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,100,000 shares of the biopharmaceutical company’s stock worth $30,580,000 after buying an additional 23,538 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Intra-Cellular Therapies during the first quarter worth $1,480,000. Bank of New York Mellon Corp increased its position in shares of Intra-Cellular Therapies by 19.1% in the second quarter. Bank of New York Mellon Corp now owns 177,317 shares of the biopharmaceutical company’s stock worth $6,884,000 after buying an additional 28,467 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in shares of Intra-Cellular Therapies during the first quarter worth $1,056,000. 70.15% of the stock is owned by institutional investors and hedge funds.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) traded up 3.55% during midday trading on Friday, reaching $42.32. 401,746 shares of the company’s stock traded hands. Intra-Cellular Therapies Inc. has a 52-week low of $22.41 and a 52-week high of $59.96. The company’s 50-day moving average price is $41.78 and its 200-day moving average price is $36.97. The stock’s market cap is $1.83 billion.
Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.08. The business earned $0.23 million during the quarter, compared to analysts’ expectations of $0.02 million. During the same period last year, the company posted ($0.61) EPS. Intra-Cellular Therapies’s revenue for the quarter was up 283.3% on a year-over-year basis. On average, equities analysts predict that Intra-Cellular Therapies Inc. will post ($3.16) EPS for the current fiscal year.
A number of equities analysts recently weighed in on ITCI shares. Piper Jaffray Cos. reissued an “overweight” rating and set a $57.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday, September 13th. Leerink Swann reissued a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, June 22nd. Cowen and Company reissued a “buy” rating and set a $75.00 target price on shares of Intra-Cellular Therapies in a research note on Friday, August 5th. Finally, Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $70.25.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.